Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental injection aims to combat Life-Threatening liver failure

NCT ID NCT06916585

Recruiting now Disease control Sponsor: Shenzhen Third People's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase II trial tests an experimental drug called AS1501 in people with acute-on-chronic liver failure (ACLF), a sudden worsening of liver function in those with chronic liver disease. The study first evaluates safety in a small group, then compares the drug against a placebo in a larger group to see if it helps improve outcomes. Participants receive the drug by injection, initially as a single dose followed by weekly doses for four weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called AS1501, given by injection
What this could lead to
If successful, this could lead to a new treatment option for acute-on-chronic liver failure, a life-threatening condition with few therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm effectiveness or safety in larger groups. There is also a risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE-ON-CHRONIC LIVER FAILURE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shenzhen Third People's Hospital

    RECRUITING

    Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.